Silaschi Miriam, Nicou Niki, Deshpande Ranjit, Chaubey Sanjay, Baghai Max, Dworakowski Rafal, Wendler Olaf
Department of Cardiothoracic Surgery, King's College Hospital London, London, UK.
Department of Cardiology, King's College Hospital London, London, UK.
Interact Cardiovasc Thorac Surg. 2017 Sep 1;25(3):343-349. doi: 10.1093/icvts/ivx109.
The choice of substitute during aortic valve replacement for infective endocarditis (IE) is still widely debated. We retrospectively reviewed all patients operated for aortic IE and compared groups according to the complexity of IE and substitutes implanted.
From 2000 to 2015, 187 patients were treated using stentless bioprostheses (SBP) as root replacement (n = 30), mechanical prostheses (MP, n = 45) or stented bioprostheses (SP, n = 112) (mean follow-up 4.6 years, survival data 100% complete).
MP patients were younger (42.5 ± 10.7 vs 57.2 ± 16.9 years [SBP], 59.1 ± 14.1 years [SP], P < 0.01), but rates of intravenous drug use and chronic dialysis were not different. SBP patients more often had root involvement (83.3% vs 33.3% [MP], 25.9% [SP], P < 0.01) and prosthetic valve endocarditis (53.3% vs 6.7% [MP], 12.5% [SP], P < 0.01). In-hospital complications and length of stay were not different. Thirty-day mortality was 13.3% [SBP], 6.7% [MP] and 12.5% [SP] (P = 0.53). Five-year survival tended to be superior in SBP (83.3% vs 77.6% [MP], 67.1% [SP], P = 0.09). In patients with complicated IE (root involvement or prosthetic valve endocarditis, n = 77), SBP had superior long-term survival (86.9% vs 81.3% [MP], 57.2% [SP], PSBP/MP = 0.07, PSBP/SP = 0.05). No early reinfection (<90 days) occurred in SBP vs 4.4% [MP] and 7.1% [SP] (P = 0.29). Reoperation for late reinfection occurred in 6.7% [SBP] vs 11.1% [MP] and 12.5% [SP] (P = 0.65). Prosthesis failure occurred in 3.3% [SBP] and 1.8% [SP] (P = 0.52).
Use of SBP provides favourable outcomes in patients with IE with low rates of reinfection and valve deterioration. It seems to be an optimal device in patients with complex IE.
感染性心内膜炎(IE)行主动脉瓣置换时替代物的选择仍存在广泛争议。我们回顾性分析了所有接受主动脉IE手术的患者,并根据IE的复杂性和植入的替代物对患者进行分组比较。
2000年至2015年,187例患者接受了无支架生物瓣(SBP)作为根部置换(n = 30)、机械瓣(MP,n = 45)或有支架生物瓣(SP,n = 112)治疗(平均随访4.6年,生存数据100%完整)。
MP组患者较年轻(42.5±10.7岁 vs 57.2±16.9岁[SBP],59.1±14.1岁[SP],P < 0.01),但静脉吸毒率和慢性透析率无差异。SBP组患者根部受累(83.3% vs 33.3%[MP],25.9%[SP],P < 0.01)和人工瓣膜心内膜炎(53.3% vs 6.7%[MP],12.5%[SP],P < 0.01)更为常见。住院并发症和住院时间无差异。30天死亡率分别为13.3%[SBP],6.7%[MP]和12.5%[SP](P = 0.53)。SBP组5年生存率有更高趋势(83.3% vs 77.6%[MP],67.1%[SP],P = 0.09)。在复杂IE患者(根部受累或人工瓣膜心内膜炎,n = 77)中,SBP有更好的长期生存率(86.9% vs 81.3%[MP],57.2%[SP],PSBP/MP = 0.07,PSBP/SP = 0.05)。SBP组未发生早期再感染(<90天),而MP组为4.4%,SP组为7.1%(P = 0.29)。晚期再感染行再次手术的比例分别为6.7%[SBP],11.1%[MP]和12.5%[SP](P = 0.65)。人工瓣膜失败率分别为3.3%[SBP]和1.8%[SP](P = 0.52)。
使用SBP治疗IE患者可获得良好预后,再感染率和瓣膜退化率较低。对于复杂IE患者,SBP似乎是最佳选择。